Biowaivers and Regulatory Exemptions

Biowaivers are regulatory exemptions granted for certain bioequivalence studies, allowing for the approval of generic drugs without conducting comparative clinical trials. These waivers are based on the demonstration of similarity in drug absorption between the generic and reference products using in vitro dissolution testing or other surrogate measures. Biowaivers streamline the drug approval process, saving time and resources while maintaining confidence in the equivalence of generic medications, particularly for well-understood drugs with predictable pharmacokinetics.

 

    Related Conference of Biowaivers and Regulatory Exemptions

    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 14-15, 2025

    35th Annual European Pharma Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Paris, France
    August 18-19, 2025

    40th World Congress on Pharmacology and Therapeutics

    Valencia, Spain
    September 22-23, 2025

    Pharma Biotech Expo

    Toronto, Canada
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    13th International Conference on Clinical Trials

    Amsterdam, Netherlands

    Biowaivers and Regulatory Exemptions Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in